ERBB2 and neoplasm: Notably, the pCR rates among HER2 IHC 2+/HER2 amplified tumours in patients who received anti-HER2 therapy were 20% in Group 1, 21% in Group 2 and 14% in Group 3, lower than the clinical trials.